logo
Share SHARE
FONT-SIZE Plus   Neg

4SC Receives Key Patent For Oncology Compound Resminostat In Japan

4SC AG (FSCGF.PK) Wednesday said it has been granted a key patent for its lead anti-cancer compound resminostat in Japan. The patent covers the composition of matter of resminostat, pharmaceutical compositions comprising resminostat and its therapeutic use in cancer and other therapeutic areas.

The company is engaged in the discovery and development of targeted small molecule drugs for autoimmune diseases and cancer. In April, 4SC granted an exclusive license to Yakult Honsha for the development and commercialization of resminostat in Japan. Hepatocellular carcinoma, the most common type of liver cancer, has a particularly high incidence in Japan.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Fresenius Kabi announced it has agreed to acquire Akorn (AKRX), a U.S.-based manufacturer and marketer of prescription and over-the-counter pharmaceutical products, for approximately $4.3 billion, or $34.00 a share, plus the assumption of approximately $450 million of debt. Akorn's largest shareholder,... Uber has been reportedly tracking user's phones, even after deleting the app. However, the company now assured that it would not continue with such tracking anymore. Qatar Airways will launch long-haul flights to twelve new destinations in 2018, including direct flights to Wales in the UK and San Francisco in the U.S. Qatar Airways plans to start direct flights to San Francisco in early 2018 as part of its growth strategy. The move comes even as the carrier's Dubai-based rival Emirates Airlines said last week that it will cut flights to five cities in the U.S.
comments powered by Disqus
Follow RTT